An interventional study of MRI scan and Radiologist training in Rectal Cancer and Colo-rectal Cancer, sponsored by Imperial College London. Recruiting at 23 sites in United Kingdom. Open to participants aged 16 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-11-04.
Sponsored by Imperial College London · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies in Rectal Neoplasms with a site in United Kingdom — 16 open to participants now, 26 under way, 5 of them phase 3. Rectal Neoplasms · United Kingdom.
Among the 113 studies in Rectal Neoplasms with a site in United Kingdom, this one is the 30th largest by planned enrollment of the 78 interventional ones that give a count, is one of 2 that started in 2024, is one of 26 with no phase, reaches primary completion later than 12 of the 25 other live ones, and was the 84th registered.
2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.
Browse Rectal Neoplasms studies →16 of the 113 studies in Rectal Neoplasms with a site in United Kingdom are open now. Recruiting first, the newest first:
Delcath Systems Inc. · Sites in United Kingdom, United States, Czechia and 6 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in United Kingdom, United States, Argentina and 26 more countries
Ages 18+
Royal Marsden NHS Foundation Trust · Sites in United Kingdom
Ages 18+
The Griffin Institute · Sites in United Kingdom
Ages 18+ · Healthy volunteers
Glasgow Royal Infirmary · Sites in United Kingdom
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 16 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 23 · Phase 3 28
First in 1994; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 65 across 1,754 interventional studies indexed under Rectal Neoplasms.
Median enrollment 115 across the 78 interventional studies, 150 across the 28 observational. Of the 58 that completed or were terminated, 8 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 113 have an industry lead sponsor. The 10 most frequent:
Imperial College London is the lead sponsor of 844 studies on the registry; 181 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
Imperial College London has 9 studies filed under Rectal Neoplasms — fewer than ten, so there is no comparison to draw.
10 of the studies in Rectal Neoplasms with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02945566Phase 3University of BirminghamCan we Save the Rectum by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer? | 2027-08 |
| NCT06607458Delcath Systems Inc.Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease | 2026-12 |
| NCT02704520Imperial College LondonMagnetic Resonance Tumour Regression Grade (mrTRG) as a Novel Biomarker - Phase III Non CTIMP Trial | 2026-12 |
| NCT02246634Imperial College LondonScreening for Synchronous Metastases in Colorectal Cancer With DW-MRI (SERENADE) | 2026-12 |
| NCT02579278Imperial College LondonCirculating Tumour DNA (ctDNA) in Patients With Colorectal Cancer and the Relationship to Imaging Features of Extramural Venous Invasion | 2026-12 |
Add all 10 to your calendar (.ics) → With an account.
Among the 113 studies in Rectal Neoplasms with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
When a patient is diagnosed with a rectal (bowel) polyp or cancer, radiology doctors read MRI scans to describe how deeply the cancer invades into the bowel wall (this is the 'stage' of the cancer). In this project, we will teach radiologists to find more early-stage rectal cancers. These are cancers that have only grown partially into the bowel wall. If we succeed, more patients could have these lesions removed by a local procedure that preserves the bowel and avoids the risks and complications of major surgery.
We have developed a new method for radiology doctors to read MRI scans, which is more accurate than current practice. Currently only 3/10 of early rectal cancers are found by radiologists but by using our MRI reading system, 9/10 patients can be accurately identified as having early rectal cancer. We have proven that we can teach this method to other radiology doctors whose reports help to accurately inform patients of all possible treatment options, so they can be offered the option of a local procedure.
In this initial work we will train radiology doctors in our MRI reading method in 20 hospitals. We will compare MRI reports before and after training to see if an accurate reading method improves treatments choices for patients. We will also determine whether more patients have local procedures after our training. The results of this initial work will help us to apply for national funding for a trial that we can quickly roll out to all NHS hospitals.
Many patients diagnosed with Early Rectal Cancer (ERC) are currently over-treated. Most patients with confirmed ERC will undergo an MRI, but some are not correctly identified in endoscopy and immediately removed. Of those who undergo MRI, 69% are over-staged and undergo major surgery or unnecessary radiotherapy when local excision surgery to preserve the patients rectum, and quality of life, would have been possible. \<10% of patients with ERC are staged accurately and offered local excision, with the majority who are staged as ERC on MRI still undergoing major surgery, likely due to uncertainty in the staging report.
Prof Gina Brown developed a more accurate radiological staging system (PRESERVE) or ERC, whereby T2 tumours are identified and classified according to the degree of preservation of the individual layers of the rectal wall. It has been shown that PRESERVE enabled better identification of ERC suitable for local excision from the expected 30% to 89% accuracy. This improved accuracy was replicated in a further study by training a cohort of 12 radiologists. It is predicted that wider adoption of PRESERVE will result in increased organ-preserving surgery from the current rates of 10% to >50%.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All sites will begin in the Control arm, with patients recruited to the Control Arm Schedule. Clinical investigations prior to treatment, during treatment, after surgery and during further treatment should be performed as per standard clinical practice and as clinically indicated. Each site will transition to the Intervention arm at a month prescribed by their randomised cluster, and from that point patients are recruited to the Intervention Arm Schedule . Patients will be recruited to either the Control or Intervention arms dependent on which arm is in progress at the site at the time of recruitment. There will be no crossover of patients between the arms at any point.
Each site will transition to the Intervention arm at a month prescribed by their randomised cluster, and from that point patients are recruited to the Intervention Arm Schedule . The transition period lasts one month during which recruitment is halted and two interventions implemented: 1. MRI scans will be recommended for all rectal polyps ≥20mm in size, or with other features suspicious of malignancy, prior to removal. This is designed to reduce the numbers of Early Rectal Cancers missed in endoscopy. 2. Radiologist training in the use of the PRESERVE mrSRT for suspected Early Rectal Cancer. Patients will be recruited to either the Control or Intervention arms dependent on which arm is in progress at the site at the time of recruitment. There will be no crossover of patients between the arms at any point.
Diagnostic Test: MRI scan · Other: Radiologist training
MRI scans will be recommended for all rectal polyps ≥20mm in size, or with other features suspicious of malignancy, prior to removal. This is designed to reduce the numbers of Early Rectal Cancers missed in endoscopy.
Radiologist training in the use of the PRESERVE mrSRT for suspected Early Rectal Cancer.
Impact of a training intervention on the accuracy of the tumour staging diagnosis through systematic reporting approach to MRI scans against current (pre intervention) practice.
Comparison of the proportion of patients with early rectal cancer who are diagnosed by pathology vs those staged as such by MRI, before and after the intervention.
Time frame: 1 year
Proportion of patients with technically adequacate scans before and after intervention
Proportion of patients scanned with high resolution MR in the correct planes
Time frame: 1 year
Proportion of primary tumour characterised by morphology and other features associated with malignancy before and after intervention
Proportion of reports where primary tumour has been characterised by morphology before and after intervention in i) endoscopy, ii) radiology reports before and after intervention
Time frame: 1 year
Proportion of MRI reports with T substage given before and after intervention
Proportion of reports where T substage of primary tumour has been recorded before and after intervention
Time frame: 1 year
Number of patients identified on imaging as suitable for rectal preservation by local excision
Proportion of imaging reports where suitable patients are identified on the report as suitable for rectal preservation by local excision being identified by the radiologist on the report before and after intervention
Time frame: 1 year
Number of patients identified by MDT as suitable for rectal preservation by local excision
Proportion of MDT decisions where patients suitable for rectal preservation by local excision are identified and comparison of treatments offered to patients by the MDT, before and after the intervention
Time frame: 1 year
Correlation of accuracy in the identification of safe plane of excision for rectal preservation by the radiologist
Proportion of patients with \>1mm muscularis preserved on histopathology identified as such by the radiologist before and after intervention Proportion of patients with \>1mm submucosa preserved on histopathology identified as such by the radiologist before and after intervention Proportion of patients undergoing TME that have \<1mm muscularis preserved on histopathology identified as such by the radiologist before and after intervention
Time frame: 1 year
Numebr of patients with R0 by local excision or TME as appropriate
Proportion of patients with R0 that have \>1mm muscularis preserved on histopathology identified as such by the radiologist before and after intervention Proportion of patients with R0 that have\>1mm submucosa preserved on histopathology identified as such by the radiologist before and after intervention Proportion of patients undergoing TME with R0 that have \<1mm muscularis preserved on histopathology identified as such by the radiologist before and after intervention
Time frame: 1 year
Qualitative EORTC QLQ-CR29 Questionnaire on Quality of Life of patients undergoing local excision vs major surgery
Comparison of QoL EORTC QLQ-CR29 scores before and after intervention. Questions relate to difficulty in performing every day tasks answers are rated 'Not at all' 'A Little' 'Quite a Bit' 'Very Much'
Time frame: 1 year, 3 years, 5 years
Qualitative EORTC QLQ-CR30 Questionnaire on Quality of Life of patients undergoing local excision vs major surgery
Comparison of QoL EORTC QLQ-CR30 scores before and after intervention. Questions relate to the presences of symptoms over the previous week answers are rated 'Not at all' 'A Little' 'Quite a Bit' 'Very Much'
Time frame: 1 year, 3 years, 5 years
Qualitative LARS Questionnaire on Quality of Life of patients undergoing local excision vs major surgery
Comparison of LARS scores before and after intervention. Questions relate to bowel function answers are rated 'Not at all' 'A Little' 'Quite a Bit' 'Very Much'
Time frame: 1 year, 3 years, 5 years
Qualitative Questionnaire on Quality of Life of patients undergoing local excision vs major surgery
Comparison of self evaluation of overall health and quality of life scores before and after intervention. Answers are rated from 1 very poor to 7 excellent
Time frame: 1 year, 3 years, 5 years
Comparison of total costs of procedures performed between patients undergoing local excision surgery to those undergoing major surgery
Comparison of total costs of hospital procedures performed based on individual pathways before and after intervention
Time frame: 1 year
Comparison of inpatient costs between patients undergoing local excision surgery to those undergoing major surgery
Comparison of cost of inpatient episodes based on individual pathways before and after intervention
Time frame: 1 year
Comparison of total cost of outpatient visits between patients undergoing local excision surgery to those undergoing major surgery
Comparison of total cost of outpatient episodes based on individual pathways before and after intervention
Time frame: 1 year
Comparison of total community costs between patients undergoing local excision surgery to those undergoing major surgery
Comparison of total cost of treatments delivered in the community based on individual pathways before and after intervention
Time frame: 1 year
Number of patients without disease and/or without stoma between patients undergoing local excision surgery, compared to those undergoing major surgery
DFS and stoma free survival in patients based on individual pathways before and after intervention
Time frame: 1 year, 3 years, 5 years
Assessment results for the effectiveness of mrSRT after a year from training
Determine longevity of training by assessment of radiologists trained with the PRESERVE mrSRT accuracy 1 year after training
Time frame: 1 year
Identification of histopathological biomarkers to improve selection of patients who can undergo rectal preserving strategies for Early Recal Cancer
Comparison of relative % histopathological biomarkers screening panels between patients identified on imaging as suitable for rectal preservation by local excision being identified by the radiologist on the report before and after intervention
Time frame: 2 months, 1 year, 3 years, 5 years
Plan to share: No
Started Sep 2024 (actual). Primary completion is estimated for Dec 2026, 27 months after the start.
Of 329 non-industry interventional studies with no phase under Rectal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 78. This study's planned 27 months is below that.
Counting every sponsor, half of 336 studies reached it within 51 months; a quarter within 23 and three quarters within 78.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.